B

Blueprint Medicines Corp
D

BPMC

92.280
USD
-2.08
(-2.20%)
مغلق
حجم التداول
25,238
الربح لكل سهم
-1
العائد الربحي
-
P/E
-86
حجم السوق
5,897,246,695
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    LLY
    LLY
    0.67
    (0.08%)
    874.04 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Blueprint Medicines Corp

القطاع: Healthcare
الصناعة: Biotechnology
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patientsliving with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.